Topical therapy for pain control in malignant fungating wounds: a scoping review protocol

v. 1, 2019 - 107601
Pôster
Favoritar este trabalho
Como citar esse trabalho?
Resumo

Background: Malignant fungating wounds (MFWs) result from the uncontrolled proliferation of cancerous cells, which cause skin rupture after surrounding tissue infiltration, creating a difficult-to-treat chronic injury. MFWs are present in 5% to 14.5% of cancer patients. They have friable tissue, bleeding easily, highly exudative, odours and also painful. MFW's related pain is explained by the resulting pressure during tumour growing process, the invasion of the skin nerve endings, and finally, the trauma caused by surgical excision and radiotherapy. Additionally, peri-wound dermatitis in high exudate MFWs is severely painful. Additionally, peri-wound dermatitis in high exudate MFWs is severely painful. Literature shows pain prevalence rates from 80.4 to 100% having the patients reporting pain as one of the worst experienced cancer-related symptoms and stating that living with an MFW is devastating. The European Cancer Nursing Society published a guideline with recommendations for the care of patients with MFWs in 2015, highlighting the importance of managing the symptoms, and confirming the lack of evidence in this topic. For this study purposes, a preliminary search was conducted on April 19, 2019, in the Cochrane and The Joanna Briggs Institute (JBI) databases, using the terms "wound" and "pain;" as result, any registered systematic review about the mentioned topic was found so far. Objective: to map the topical therapies used to control pain in MFWs. Review Question: Which topical therapies used to control MFWs’ pain are reported in the literature? Method: This is a scoping review following the JBI methodology.

Instituições
  • 1 Universidade de São Paulo
Eixo Temático
  • Produção de evidências
Palavras-chave
wounds and injuries
Neoplasms
Pain